These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19389496)

  • 21. Clinical trials referral resource. Current clinical trials in multiple myeloma.
    Davis T; Schoenfeldt M
    Oncology (Williston Park); 2004 Feb; 18(2):196-8, 203. PubMed ID: 15008057
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice.
    SanMiguel J; Facon T; Cavo M
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):s4-s10. PubMed ID: 18567204
    [No Abstract]   [Full Text] [Related]  

  • 23. New strategies in transplantation therapy.
    Harousseau JL
    Oncology (Williston Park); 2004 Nov; 18(13):1614-5, 1617. PubMed ID: 15648294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Autologous stem cell transplantation in multiple myeloma - pro].
    Goldschmidt H
    Dtsch Med Wochenschr; 2009 Sep; 134(39):1942. PubMed ID: 19760555
    [No Abstract]   [Full Text] [Related]  

  • 25. High-dose chemotherapy followed by autologous stem-cell transplantation in liver-transplanted multiple myeloma patients: a report of two cases.
    Peterlin P; Gastinne T; Moreau P; Harousseau JL; Le Gouill S
    Transplantation; 2009 Feb; 87(4):617-8. PubMed ID: 19307803
    [No Abstract]   [Full Text] [Related]  

  • 26. Stem cell transplant for first relapse from the multiple myeloma research foundation.
    Anderson KC; Vesole DH
    Oncology (Williston Park); 2006 Dec; 20(14):1818, 1820-1, 1825-6. PubMed ID: 17263130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.
    Nucci M; Anaissie E
    Clin Infect Dis; 2009 Oct; 49(8):1211-25. PubMed ID: 19769539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Positioning of autoPBSCT in the treatment of multiple myeloma in the era of new drugs].
    Matsumura I
    Nihon Rinsho; 2015 Jan; 73(1):80-4. PubMed ID: 25626309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy of mantle cell lymphoma: current standards and future strategies.
    Schmidt C; Dreyling M
    Hematol Oncol Clin North Am; 2008 Oct; 22(5):953-63, ix. PubMed ID: 18954745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VI. Autologous stem cell transplantation and maintenance therapy.
    Moreau P
    Hematol Oncol; 2013 Jun; 31 Suppl 1():42-6. PubMed ID: 23775648
    [No Abstract]   [Full Text] [Related]  

  • 31. [Efficacy of novel agents for patients with newly diagnosed symptomatic multiple myeloma].
    Sunami K
    Rinsho Ketsueki; 2012 Jun; 53(6):580-6. PubMed ID: 22790632
    [No Abstract]   [Full Text] [Related]  

  • 32. Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.
    Cook G
    Bone Marrow Transplant; 2015 Oct; 50(10):1269-70. PubMed ID: 26237169
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal mobilization method and CD34+ dose calculation for autologous PBSC transplant in myeloma patients: two important unresolved questions.
    Alegre A
    Bone Marrow Transplant; 2009 Apr; 43(8):593-5. PubMed ID: 19384344
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT.
    Avivi I; Avraham S; Koren-Michowitz M; Zuckerman T; Aviv A; Ofran Y; Benyamini N; Nagler A; Rowe JM; Nagler RM
    Bone Marrow Transplant; 2009 May; 43(10):801-6. PubMed ID: 19029961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation and monitoring of response to therapy in multiple myeloma.
    Rajkumar SV; Dispenzieri A
    Haematologica; 2005 Oct; 90(10):1305-8. PubMed ID: 16219565
    [No Abstract]   [Full Text] [Related]  

  • 38. [Multiple myeloma relapsed or progressed as plasmacytoma after allogeneic reduced-intensity stem cell transplantation: report of three cases].
    Sugimoto Y; Nishii K; Miyata E; Fujieda A; Yamaguchi M; Masuya M; Katayama N
    Rinsho Ketsueki; 2009 Apr; 50(4):289-94. PubMed ID: 19404022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing risk-adapted therapy for multiple myeloma: the Mayo perspective.
    Lonial S
    Mayo Clin Proc; 2007 Mar; 82(3):279-81. PubMed ID: 17352362
    [No Abstract]   [Full Text] [Related]  

  • 40. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
    Trigg ME; Inverso DM
    Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.